Status:
UNKNOWN
Enhanced Transcutaneous Delivery of Betamethasone for the Treatment of Vitiligo
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Conditions:
Vitiligo
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Vitiligo is the commonest acquired depigmenting disorder characterized by loss of melanocytes from the basal layer of skin causing white patches which leads to great psychological distress in many pat...
Detailed Description
Vitiligo is a psychologically devastating disorder. The fact that it typically occurs in exposed areas (the face and hands) has a major impact on self-esteem and perception of self. While lesions are ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Symmetric vitiligo
- Stable vitiligo for at least six months (\< 10% change in the last 6 months)
- Diagnosis was made clinically by a dermatologist
- Age over 18 -70 years men and women
- Exclusion criteria:
- Non Stable vitiligo
- Contraindications for phototherapy
- Pregnancy or lactation
- Lack of willingness to go to phototherapy 3 times a week for at least 6 months
- Segmental Vitiligo
- Phototherapy or topical therapy for vitiligo in the last 1 month.
- Exit criteria:
- Intolerable to the the study treatment
- Lack of patient's compliance
Exclusion
Key Trial Info
Start Date :
January 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05233735
Start Date
January 1 2021
End Date
December 31 2024
Last Update
February 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Dermatology, Tel Aviv Sourasky medical center
Tel Aviv, Israel, 64239